Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for hereditary hematological disorders.

R W Herzog1, J N Hagstrom

  • 1Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA. rwherzog@mail.med.upenn.edu

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|August 15, 2002
PubMed
Summary

Gene therapy has advanced, successfully treating X-linked severe combined immunodeficiency (SCID-X1). Current research focuses on gene therapy for inherited blood disorders like hemophilia, with promising clinical trials underway.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovating immune tolerance induction for haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Induction of tolerance to factor VIII by transient co-administration with rapamycin.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Progress and prospects: immune responses to viral vectors.

Gene therapy·2009
Same author

Role of regulatory T cells in tolerance to coagulation factors.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells.

Journal of thrombosis and haemostasis : JTH·2009
Same author

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.

Journal of thrombosis and haemostasis : JTH·2007

Area of Science:

  • * Hematology
  • * Genetic Medicine
  • * Immunology

Background:

  • * The first successful gene therapy in 2000 treated pediatric patients with X-linked severe combined immunodeficiency (SCID-X1), utilizing autologous CD34+ hematopoietic cells and ex vivo retroviral gene transfer.
  • * Significant preclinical and clinical research is dedicated to developing gene therapies for various inherited hematological disorders, including hemophilia, Fanconi anemia, sickle cell disease, and beta-thalassemia.

Purpose of the Study:

  • * To review the progress and current status of gene therapy development for inherited hematological disorders.
  • * To highlight advances in hemophilia treatment, including ongoing clinical trials for hemophilia A and B.

Main Methods:

  • * Ex vivo gene transfer using retroviral vectors for SCID-X1 treatment.

Related Experiment Videos

  • * Preclinical and clinical studies investigating various gene transfer techniques (retroviral, non-viral, adeno-associated viral vectors) for hemophilia.
  • * In vivo administration of viral vectors (AAV) for factor IX expression in hemophilia B.

    • Main Results:

    • * Successful immune reconstitution in pediatric SCID-X1 patients following gene therapy.
    • * Ongoing Phase I clinical trials for hemophilia A and B demonstrate progress in safety and feasibility.
    • * Preclinical and clinical data indicate the safe administration of high-dose viral vectors in vivo for hemophilia treatment.

    Conclusions:

    • * Gene therapy has evolved significantly since the initial success in treating SCID-X1.
    • * Hemophilia treatment is a key area of advancement, with multiple clinical trials exploring novel gene therapy approaches.
    • * The safe in vivo administration of viral vectors represents a critical step forward in treating inherited blood disorders.